Therapy Areas: Infectious Diseases
Eurofins completes acquisition of Transplant Genomics
25 June 2019 -

Eurofins Scientific (Paris:ERF), a scientific leader in bioanalytical testing, announced on Tuesday that it has successfully closed the acquisition of Transplant Genomics Inc (TGI), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics.

Financial details of this acquisition were not available.

Reportedly, TGI's innovative non-invasive tests for the management of patients with silent inflammation and rejection following kidney transplants will strengthen and complement Eurofins' global Transplant Diagnostics offering, which includes VRL Inc, the largest pre-transplant laboratory in the US, and Viracor Inc, the largest specialty post-transplant clinical laboratory in the US.

Viracor currently serves approximately 70% of all transplant programmes in the US, focusing on post-transplant infectious disease and immune status monitoring services.

Also, Eurofins' Transplant Diagnostics capabilities and market footprint provide an ideal platform in which to launch TGI's highly anticipated TruGraf blood gene expression test, capable of reliably ruling out 'silent' subclinical kidney rejection in kidney transplant patients with stable kidney function.

Also, TGI has recently received a draft Local Coverage Determination (LCD) decision from Centers for Medicare & Medicaid Services (CMS) via Palmetto GBA's Molecular Diagnostic Services (MolDX) Programme, supporting the upcoming launch of TruGraf.

Transplant Genomics is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients.

Login
Username:

Password: